Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00930930 · ClinicalTrials.gov registry record · Phase 2
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
- 8
- Study locations
NCT00930930 is a Phase 2 study of Breast Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 145 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT00930930, a Phase 2 study of Breast Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
- 8
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving chemotherapy together with everolimus before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether cisplatin and paclitaxel are more effective when given together with or without everolimus in treating patients with breast cancer. PURPOSE: This randomized phase II trial is studying how well cisplatin and paclitaxel work when given together with or without everolimus in treating patients with stage II or stage III breast cancer.
Conditions Studied
Interventions
- OTHER placebo
- DRUG cisplatin
- DRUG paclitaxel
- DRUG everolimus
- PROCEDURE Venous blood draw
Study Locations (8)
Tennessee
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- MBCCOP - Meharry Medical College - Nashville - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Alabama
- University of Alabama - Birmingham
Mississippi
- University of Mississippi Medical Center Research Institute - Jackson
Pennsylvania
- Hershey Medical Center - Hershey
Texas
- The Methodist Hospital Research Institute - Houston
Virginia
- University of Virginia Health Sciences Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00930930
The ClinicalTrials.gov registry entry for NCT00930930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which placebo is the first listed.
NCT00930930 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Tennessee, Alabama, Mississippi.
Frequently Asked Questions
What is clinical trial NCT00930930 about?
NCT00930930 is a clinical study titled "Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and b...
What is the current status of trial NCT00930930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2009-06. Estimated completion is 2014-10.
What conditions does trial NCT00930930 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00930930?
The interventions under investigation include: placebo (OTHER), cisplatin (DRUG), paclitaxel (DRUG), everolimus (DRUG), Venous blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT00930930?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00930930 being conducted?
This trial has 8 study locations across Alabama, Mississippi, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.